427 related articles for article (PubMed ID: 21122312)
21. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
[TBL] [Abstract][Full Text] [Related]
22. [Effect of graft-versus-host disease on relapse and survival in 100 patients after allogeneic hematopoietic stem cell transplantation].
Deng XR; Ren HY; Cen XN; Wang LH; Liang ZY; Wang WS; Qiu ZX; Ou JP; Xu WL; Wang MJ; Li Y; Yin Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):994-8. PubMed ID: 19698246
[TBL] [Abstract][Full Text] [Related]
23. [Sequential intensified conditioning followed by graft-versus-leukemia induction could prevent relapse of refractory acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Xuan L; Fan Z; Zhang Y; Huang F; Dai M; Li Y; Nie D; Lin D; Jiang Q; Sun J; Xiao Y; Liu Q
Zhonghua Yi Xue Za Zhi; 2015 Jun; 95(24):1915-20. PubMed ID: 26710693
[TBL] [Abstract][Full Text] [Related]
24. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
25. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
[TBL] [Abstract][Full Text] [Related]
26. The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia.
Yeshurun M; Weisdorf D; Rowe JM; Tallman MS; Zhang MJ; Wang HL; Saber W; de Lima M; Sandmaier BM; Uy G; Kamble RT; Cairo MS; Cooper BW; Cahn JY; Ganguly S; Camitta B; Verdonck LF; Dandoy C; Diaz MA; Savani BN; George B; Liesveld J; McGuirk J; Byrne M; Grunwald MR; Drobyski WR; Pulsipher MA; Abdel-Azim H; Prestidge T; Wieduwilt MJ; Martino R; Norkin M; Beitinjaneh A; Seo S; Nishihori T; Wirk B; Frangoul H; Bashey A; Mori S; Marks DI; Bachanova V
Blood Adv; 2019 Feb; 3(4):670-680. PubMed ID: 30808685
[TBL] [Abstract][Full Text] [Related]
27. [Methotrexate for treatment of graft versus host disease after allogeneic hematopoietic stem cell transplantation].
Huang XJ; Jiang Q; Chen H; Xu LP; Liu DH; Chen YH; Han W; Zhang YC; Liu KY; Lu DP
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(16):1097-101. PubMed ID: 16029565
[TBL] [Abstract][Full Text] [Related]
28. Immunosuppression for 6-8 weeks after modified donor lymphocyte infusion reduced acute graft-versus-host disease without influencing graft-versus-leukemia effect in haploidentical transplant.
Yan C; Xu L; Liu D; Chen H; Wang Y; Liu K; Huang X
Chin Med J (Engl); 2014; 127(20):3602-9. PubMed ID: 25316237
[TBL] [Abstract][Full Text] [Related]
29. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
[TBL] [Abstract][Full Text] [Related]
30. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
Lin Q; Dong M; Wang QM; Wen JY; Wu XY
Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
[TBL] [Abstract][Full Text] [Related]
31. Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions.
Schaap N; Schattenberg A; Bär B; Preijers F; van de Wiel van Kemenade E; de Witte T
Leukemia; 2001 Sep; 15(9):1339-46. PubMed ID: 11516094
[TBL] [Abstract][Full Text] [Related]
32. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
33. Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Yuan XL; Tan YM; Shi JM; Zhao YM; Yu J; Lai XY; Yang LX; Huang H; Luo Y
Ann Hematol; 2021 Feb; 100(2):517-527. PubMed ID: 33128124
[TBL] [Abstract][Full Text] [Related]
34. [Effects of allogeneic hematopoietic stem cell transplantation with very-high-dose conditioning regimen for refractory leukemia].
Liu QF; Sun J; Xu D; Zhang Y; Fan ZP; Wei YQ; Meng FY; Zhou SY
Di Yi Jun Yi Da Xue Xue Bao; 2004 Oct; 24(10):1117-9. PubMed ID: 15485779
[TBL] [Abstract][Full Text] [Related]
35. [Prophylactic G-CSF mobilized donor lymphocytes infusion after non-myeloablative stem cell transplantation prevents relapse in patients with high-risk leukemia].
Zhao HX; Sun WJ; Li J; Qiao JX; Huang YJ; Hu HL; Ai HS
Zhonghua Xue Ye Xue Za Zhi; 2013 Nov; 34(11):922-5. PubMed ID: 24294845
[TBL] [Abstract][Full Text] [Related]
36. [Impact of graft versus host disease on outcome of allogeneic peripherial blood stem cell transplantation for leukemia].
Li M; Zhang W; Wang J; Song X; Yang J; Ni X; Yang D; Chen L; Chen J; Hu X; Gao L; Qiu H; Zhou H; Cheng H
Zhonghua Xue Ye Xue Za Zhi; 2014 May; 35(5):428-33. PubMed ID: 24857214
[TBL] [Abstract][Full Text] [Related]
37. New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT.
Chang X; Zang X; Xia CQ
Bone Marrow Transplant; 2016 Mar; 51(3):324-32. PubMed ID: 26595077
[TBL] [Abstract][Full Text] [Related]
38. Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions.
Burt RK; Drobyski WR; Seregina T; Traynor A; Oyama Y; Keever-Taylor C; Stefka J; Kuzel TM; Brush M; Rodriquez J; Burns W; Tennant L; Link C
Exp Hematol; 2003 Oct; 31(10):903-10. PubMed ID: 14550806
[TBL] [Abstract][Full Text] [Related]
39. Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: A nationwide retrospective study.
Itonaga H; Iwanaga M; Aoki K; Aoki J; Ishiyama K; Ishikawa T; Sakura T; Fukuda T; Najima Y; Yujiri T; Mori T; Kurokawa M; Nawa Y; Uchida N; Morishita Y; Hashimoto H; Eto T; Hirokawa M; Morishima Y; Nagamura-Inoue T; Atsuta Y; Miyazaki Y
Leuk Res; 2016 Feb; 41():48-55. PubMed ID: 26754557
[TBL] [Abstract][Full Text] [Related]
40. Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Ann Hematol; 2017 May; 96(5):829-838. PubMed ID: 28285386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
